Number of Respondents: 313,825; Total Annual Responses: 313,825; Total Annual Hours: 571,488.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access CMS' Web site address at http://www.hcfa.gov/regs/ prdact95.htm, or e-mail your request, including your address, phone number, OMB number, and CMS document identifier, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections must be mailed within 30 days of this notice directly to the OMB desk officer: OMB Human Resources and Housing Branch, Attention: Allison Eydt, New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: January 23, 2002.

#### John P. Burke, III,

CMS Reports Clearance Officer, CMS Office of Information Services, Security and Standards Group, Division of CMS Enterprise Standards.

[FR Doc. 02–2451 Filed 1–31–02; 8:45 am]

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Center for Medicare and Medicaid Services

[Document Identifier: CMS-10044]

## Agency Information Collection Activities: Submission for OMB Review; Comment Request

**AGENCY:** Center for Medicare and Medicaid Services, HHS.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Center for Medicare and Medicaid Services (CMS) (formerly known as the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Type of Information Collection Request: New Collection; Title of Information Collection: Medicare Lifestyle Modificatoin Program Demonstration; Form No.: CMS-10044 (OMB# 0938–NEW); *Use:* This demonstration will focus on two Medicare sponsored, lifestyle modification programs designed to reverse, reduce or ameliorate the progression of coronary artery disease (CAD) at risk for significant morbidity and mortality. This demonstration will test the cost-effectiveness and feasibility of providing payment for cardiovascular lifestyle modification program services to Medicare beneficiaries.; Frequency: Baseline Enrollment, 12 and 24 months; Affected Public: Individuals or Households; Number of Respondents:  $2,\!240; \textit{Total Annual Responses: } 1,\!680;$ Total Annual Hours: 1,106.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access CMS' Web site address at http://www.hcfa.gov/regs/ prdact95.htm, or e-mail your request, including your address, phone number, OMB number, and CMS document identifier, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections must be mailed within 30 days of this notice directly to the OMB desk officer: OMB Human Resources and Housing Branch, Attention: Allison Eydt, New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: January 24, 2002.

### John P. Burke, III,

CMS Reports Clearance Officer, CMS Office of Information Services, Security and Standards Group, Division of CMS Enterprise Standards.

[FR Doc. 02–2454 Filed 1–31–02; 8:45 am] BILLING CODE 4120–03–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Food and Drug Administration

## Best Practices for Reducing Transfusion Errors; Public Workshop

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of public workshop.

The Food and Drug Administration (FDA) is announcing the following public workshop: Best Practices for Reducing Transfusion Errors. The

purpose of the public workshop is to discuss practices and techniques that may decrease transfusion errors, including systems and technology that can be applied to reducing transfusion errors.

Date and Time: The public workshop will be held on February 14, 2002, from 8:30 a.m. to 5 p.m., and February 15, 2002, from 8:30 a.m. to 12:30 p.m.

Location: The public workshop will be held at the Natcher Conference Center, National Institutes of Health, Bldg. 45, 45 Center Dr., 8600 Rockville Pike, Bethesda, MD.

Contact: Joseph Wilczek, Center for Biologics Evaluation and Research (HFM–302), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–6129, FAX 301–827–2843.

Registration: Send registration information (including name, title, firm name, address, telephone, and fax number) to the contact person by February 5, 2002. Onsite registration on a space available basis will begin at 7:30 a.m. on the days of the workshop. There is no registration fee. If you need special accommodations due to a disability, please contact Joseph Wilczek at least 7 days in advance.

Transcripts: Transcripts of the public workshop may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A–16, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page. The public workshop transcript will also be available on the Internet at http://www.fda.gov/cber/minutes/workshop-min.htm.

SUPPLEMENTARY INFORMATION: FDA and the Agency for Healthcare Research and Quality, Department of Health and Human Services, are cosponsoring a public workshop on avoiding errors in transfusion medicine. On the first day of the workshop, topics to be discussed include: Patient and medication identification, errors in manufacturing and testing of blood and blood components, system errors and cultural factors, and the role of product deviation reporting in reducing transfusion errors. The second day of the workshop will address current as well as future technology trends that should help prevent transfusion errors. The public workshop agenda is posted on the Internet at http://www.fda.gov/ cber/meetings/trnfsnerr021402.htm.

Dated: January 28, 2002.

#### Margaret M. Dotzel,

Associate Commissioner for Policy.
[FR Doc. 02–2550 Filed 1–31–02; 8:45 am]
BILLING CODE 4160–01–8

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

**Substance Abuse and Mental Health Services Administration** 

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS. **ACTION:** Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A notice listing all currently certified laboratories is published in the Federal Register during the first week of each month. If any laboratory's certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at the following Web sites: http://workplace.samhsa.gov;http://www.drugfreeworkplace.gov;and http://www.health.org/workplace.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, 5600 Fishers Lane, Rockwall 2 Building, Room 815, Rockville, Maryland 20857; Tel.: (301) 443–6014, Fax: (301) 443–

### SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal
Workplace Drug Testing were developed
in accordance with Executive Order
12564 and section 503 of Pub. L. 100–
71. Subpart C of the Guidelines,
"Certification of Laboratories Engaged
in Urine Drug Testing for Federal
Agencies," sets strict standards which
laboratories must meet in order to
conduct urine drug testing for Federal
agencies. To become certified an
applicant laboratory must undergo three
rounds of performance testing plus an
on-site inspection.

To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

- ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328–7840/800– 877–7016 (Formerly: Bayshore Clinical Laboratory)
- ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 716–429–2264 Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901–794–5770/888–290–1150
- Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615–255–2400
- Alliance Laboratory Services, 3200 Burnet Ave., Cincinnati, OH 45229, 513–585–9000 (Formerly: Jewish Hospital of Cincinnati, Inc.)
- American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 20151, 703– 802–6900
- Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119–5412, 702–733–7866/ 800–433–2750
- Baptist Medical Center—Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, 501–202–2783 (Formerly: Forensic Toxicology Laboratory Baptist Medical Center)
- Clinical Laboratory Partners, LLC, 129 East Cedar St., Newington, CT 06111, 860–696– 8115 (Formerly: Hartford Hospital Toxicology Laboratory)
- Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215–2802, 800–445–6917
- Cox Health Systems, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800–876–3652/ 417–269–3093 (Formerly: Cox Medical Centers)
- Diagnostic Services Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913, 941–561–8200/800–735–5416
- Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31602, 912–244– 4468
- DrugProof, Divison of Dynacare, 543 South Hull St., Montgomery, AL 36103, 888–777– 9497/334–241–0522 (Formerly: Alabama Reference Laboratories, Inc.)
- DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 206–386–2672/800–898–0180 (Formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)
- DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, 215–674–9310

- Dynacare Kasper Medical Laboratories \*, 14940–123 Ave., Edmonton, Alberta, Canada T5V 1B4, 780–451–3702/800–661– 9876
- ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 662–236–2609
- Express Analytical Labs, 3405 7th Avenue, Suite 106, Marion, IA 52302, 319–377– 0500
- Gamma-Dynacare Medical Laboratories \*, A Division of the Gamma-Dynacare Laboratory Partnership, 245 Pall Mall St., London, ONT, Canada N6A 1P4, 519–679– 1630
- General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608–267– 6267
- Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, 504–361– 8989/800–433–3823 (Formerly: Laboratory Specialists, Inc.)
- LabOne, Inc., 10101 Renner Blvd., Lenexa, KS 66219, 913–888–3927/800–728–4064 (Formerly: Center for Laboratory Services, a Division of LabOne, Inc.)
- Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713–856–8288/800–800–2387
- Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526– 2400/800–437–4986 (Formerly: Roche Biomedical Laboratories, Inc.)
- Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709, 919–572–6900/800–833– 3984 (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc., CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group)
- Laboratory Corporation of America Holdings, 10788 Roselle Street, San Diego, CA 92121, 800–882–7272 (Formerly: Poisonlab, Inc.)
- Laboratory Corporation of America Holdings, 1120 Stateline Road West, Southaven, MS 38671, 866–827–8042/800–233–6339 (Formerly: LabCorp Occupational Testing Services, Inc., MedExpress/National Laboratory Center)
- Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, 715–389–3734/800– 331–3734
- MAXXAM Analytics Inc.\*, 5540 McAdam Rd., Mississauga, ON, Canada L4Z 1P1, 905–890–2555 (Formerly: NOVAMANN (Ontario) Inc.)
- Medical College Hospitals Toxicology Laboratory, Department of Pathology, 3000 Arlington Ave., Toledo, OH 43699, 419– 383–5213
- MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 651–636–7466/ 800–832–3244
- MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503– 413–5295/800–950–5295
- Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, Minnesota 55417, 612–725–2088
- National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661–322–4250/800–350–3515